Craig Crews

Craig Crews has a diverse work experience spanning several companies and roles. Craig founded Siduma Therapeutics in 2021 and Halda Therapeutics in 2019. Prior to that, they were a John C. Malone Professor of Mol., Cellular, and Developmental Biology; Chemistry; Pharmacology at Yale University since 1995. In 2013, they founded Arvinas and in 2003, they co-founded Proteolix. Craig also served as the Executive Director at the Yale Center for Molecular Discovery since 2003.

Craig Crews completed their Bachelor's degree in Chemistry from the University of Virginia from 1982 to 1986. Following that, they pursued further studies at the University of Tübingen as a DAAD Fellow in Microbiology for the year 1986 to 1987. Subsequently, they attended Harvard University, where they completed their Doctor of Philosophy (Ph.D.) in Biochemistry from 1987 to 1992. Craig continued their education at Harvard University as a Cancer Research Institute Fellow in Chemical Biology from 1992 to 1995.